Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Iovance Biotherapeutics, Inc. (IOVA : NSDQ)

• Company Description    Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells. Number of Employees: 975

• Price / Volume Information    Yesterday's Closing Price: $3.86 Daily Weekly Monthly 20 Day Moving Average: 14,580,008 shares Shares Outstanding: 411.96 (millions) Market Capitalization: $1,590.17 (millions) Beta: 0.68 52 Week High: $4.57 52 Week Low: $1.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 51.37% 52.70% 12 Week 75.46% 75.24% Year To Date 41.39% 40.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 825 INDUSTRIAL ROAD SUITE 100 - SAN CARLOS,CA 94070 USA ph: 650-260-7120 fax: - ir@iovance.com http://www.iovance.com

• General Corporate Information    Officers Frederick G. Vogt - Interim Chief Executive Officer;President and Gene Corleen Roche - Chief Financial Officer Michael Weiser - Director Ryan D. Maynard - Director Iain Dukes - Director Peer Information Iovance Biotherapeutics, Inc. (CORR.) Iovance Biotherapeutics, Inc. (RSPI) Iovance Biotherapeutics, Inc. (CGXP) Iovance Biotherapeutics, Inc. (BGEN) Iovance Biotherapeutics, Inc. (GTBP) Iovance Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 462260100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 411.96 Most Recent Split Date: 9.00 (0.01:1) Beta: 0.68 Market Capitalization: $1,590.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.19 Price/Cash Flow: - Price / Sales: 6.04 EPS Growth vs. Year Ago Period: 30.77% vs. Previous Quarter: 28.00% Sales Growth vs. Year Ago Period: 17.66% vs. Previous Quarter: 28.55% ROE 12/31/25 - -54.54 09/30/25 - -55.24 06/30/25 - -52.87 ROA 12/31/25 - -42.36 09/30/25 - -43.11 06/30/25 - -41.31 Current Ratio 12/31/25 - 3.20 09/30/25 - 3.41 06/30/25 - 3.27 Quick Ratio 12/31/25 - 2.83 09/30/25 - 3.00 06/30/25 - 2.89 Operating Margin 12/31/25 - -148.41 09/30/25 - -158.78 06/30/25 - -161.44 Net Margin 12/31/25 - -148.41 09/30/25 - -158.78 06/30/25 - -161.44 Pre-Tax Margin 12/31/25 - -149.16 09/30/25 - -159.06 06/30/25 - -161.36 Book Value 12/31/25 - 1.76 09/30/25 - 1.77 06/30/25 - 2.09 Inventory Turnover 12/31/25 - 3.17 09/30/25 - 3.07 06/30/25 - 3.13 Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©